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Cause of the Most Feared
Stent Thrombosis
In their white paper, Holmes, Jr. et al. (1) do not refer to hyper-
sensitivity coronary syndrome.
However, I strongly believe that stent thrombosis (ST) is
principally a manifestation of Kounis hypersensitivity coronary
syndrome (2), caused by an “antigenic complex” of nickel alloys,
polymers, eluted drugs, and possibly concomitant oral antiplate-
let drugs and environmental exposures. Thus far, all clinical
reports and reported pathologic findings in all patients who
have died of ST, and all animal studies and experiments, point
toward hypersensitivity inflammation with infiltration of vari-
ous interrelated and interacting inflammatory cells, including
eosinophils, macrophages, T cells, and mast cells. Following are
some examples (3–5):
• In patients who developed ST associated with generalized
allergic reactions, induced by environmental causes, stents act
like magnets attracting inflammatory cells and constitute the
area of possible intracoronary mast cell and platelet activation
in order to develop ST.
• In the Research on Adverse Drug Events and Reports
project, definite ST cases showed peripheral eosinophilia and
raised immunoglobulin E titers over 5 times normal, together
with eosinophilic thrombus infiltration.
• In serum sickness–like reactions after sirolimus-eluting
stent implantation, symptoms did not resolve after the
discontinuation of clopidogrel and substitution with ticlo-
pidine, but they resolved with prednisone. However,
prednisone abolished symptoms despite aspirin and clopi-
dogrel continuation.
• In occluded biliary stents, pathology revealed infiltration of
eosinophils and lymphocytes compatible with nickel allergic
reaction.
• In thrombus sections stained with hematoxylin and eosin,
neutrophils and eosinophils were associated with stent appo-
sition, suggesting an allergic hypersensitivity reaction.
• In sirolimus-eluting stents, localized coronary hypersensitiv-
ity vasculitis and acute myocardial infarction were induced
from late ST.
• In patients who received stents and died of multivessel spasm,
histologic findings revealed inflammatory cells in the intima
and adventitia. Giemsa staining showed few scattered mast
cells.
I wonder how many of us have noticed that manufacturers’
information sheets accompanying the new generation of stents
state clearly that they are contraindicated for use in patients with
hypersensitivity to any stent component.
In conclusion, antigen-free stents should be implanted to avoid
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Stent Thrombosis
Did Biodegradable Polymers
Fail or Are We Too Impatient?
We read with interest the report by Holmes et al. (1), in which the
current knowledge about stent thrombosis is revisited, and the
possibility that biodegradable polymers improve the long-term
safety of drug-eluting stents is mentioned. Durable polymers are
associated with persistent arterial wall inflammation and delayed
vascular healing, both related to stent thrombosis (2). New
biodegradable polymers completely degrade in 6 to 9 months,
leaving behind only the bare-metal stent structure.
Apart from the LEADERS (Limus Eluted From a Durable
Versus Erodable Stent Coating) trial (3), many trials have com-
pared biodegradable with durable polymers. We have performed a
meta-analysis of 7 randomized trials comparing durable with
biodegradable polymers (COSTAR-II [Cobalt Chromium Stent
With Antiproliferative for Restenosis II], ISAR-TEST-3 [Intra-
coronary Stenting and Angiographic Results: Test Efficacy of
Rapamycin-Eluting Stents With Different Polymer Coating Strat-
egies], ISAR-TEST-4 [Intracoronary Stenting and Angiographic
Results: Test Efficacy of 3 Limus-Eluting Stents], LEADERS,
NOBORI-CORE [A Prospective, Non-Randomized, Multi-
Center Comparative Study of Nobori Drug Eluting Stent Systems
Versus Cypher Drug Eluting Stent System], NOBORI-I [A
Prospective, Randomized, Multi-Centre Comparison of Nobori
and Taxus Drug Eluting Stent Systems], and NEVO
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August 16, 2011:883–7ResElution-I) (3), including more than 7,000 patients, and found
no differences in the rate of stent thrombosis during the first year
(1.2% vs. 1.2%; odds ratio: 1.01; 95% confidence interval: 0.66 to
1.55; p  0.96) (Fig. 1).
Nevertheless, the potential benefits of biodegradable polymers
should be evaluated with longer follow-up. In fact, when we
analyzed only late (1 month) stent thrombosis, a 40% relative
risk reduction in the rate of stent thrombosis, although not
statistically significant, was found in patients allocated to biode-
gradable polymer stents (0.27% vs. 0.45%, respectively; odds ratio:
0.68; 95% confidence interval: 0.32 to 1.48; p  0.33).
We believe that biodegradable polymers will contribute to
improve the long-term safety of drug-eluting stents, but we will
have to wait for evidence from long-term (several years) follow-up
in large randomized trials.
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Reply
We appreciate the comments of Dr. Salinas and colleagues regarding
our paper (1). The safety of new-generation stents is improving. This
may be the result of several factors, one of which may be the use of
“biodegradable” polymers; other factors may also be as important,
including improved antiplatelet therapy, longer duration of antiplate-
let therapy, and improved initial stent placement using high-pressure
balloons or guidance with intravascular ultrasound and/or optical
computed tomography. Of interest, in the authors’ meta-analysis,
there were 43 patients in the biodegradable group and 41 in the
permanent polymer group. The numbers are therefore small, although
any event is often catastrophic for the individual patient. Given the
low incidence of the phenomenon and the changing technology,
larger series and longer follow-up will be needed, although challeng-
ing. At the present time, a randomized trial with stent thrombosis as
the primary end point is unavailable for study.
We also appreciate the comments of Prof. Kounis regarding
Kounis syndrome. There are multiple issues involved in stent throm-
bosis. Some issues relate to the underlying coronary artery disease,
some to the specific stent design, including bare-metal versus drug-
eluting stents, and for drug-eluting stents in particular the specific
polymer and drug or drugs used. In addition, there are issues of
compliance with and response to dual-antiplatelet therapy. Findings
consistent with hypersensitivity have been seen in some autopsy series,
as mentioned by Prof. Kounis, and may play a role. Continuing
ongoing experience with polymer-free designs as well as different
drugs may help resolve some of the issues. Fortunately, the incidence
of this often catastrophic complication is very low; this very fact makes
reaching definitive evidence-based conclusions about preventive strat-
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